Related Experiment Video
Updated: May 13, 2026
04:01
Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
Published on: September 15, 2023
Video-assisted selective lateral neck dissection for papillary thyroid carcinoma.
Bo Wu1, Zheng Ding, Youben Fan
1Department of Surgery, Affiliated Sixth People's Hospital, Shanghai Jiaotong University, Shanghai 200233, China.
Langenbeck'S Archives of Surgery
|March 16, 2013
Summary
Video-assisted selective lateral neck dissection (VASLND) is a safe and feasible minimally invasive technique for selected papillary thyroid carcinoma (PTC) patients. This approach offers excellent cosmetic results and reduced pain, with no observed recurrence during follow-up.
Area of Science:
- Surgical Oncology
- Minimally Invasive Surgery
- Head and Neck Surgery
Background:
- Minimally invasive video-assisted thyroidectomy (MIVAT) and central neck dissection (CND) for papillary thyroid microcarcinoma (PTMC) are established procedures.
- The study explores the application of video-assisted selective lateral neck dissection (VASLND) for papillary thyroid carcinoma (PTC).
Purpose of the Study:
- To evaluate the feasibility and safety of VASLND for selected PTC patients.
- To assess the oncological and cosmetic outcomes of VASLND.
Main Methods:
- Twenty-six PTC patients with unilateral tumors and suspected lymph node metastasis underwent VASLND between March 2009 and January 2012.
- The procedure involved dissection of central and lateral neck compartments.
Main Results:
- VASLND was successfully performed in all 26 patients with a mean operative time of 46 minutes.
- No major complications were reported, with an average hospital stay of 3.6 days.
- The procedure yielded a mean of 7.3 central and 8.3 lateral lymph nodes, with no observed disease recurrence during follow-up and excellent cosmetic results.
Conclusions:
- VASLND is a feasible and safe surgical option for selected PTC cases, offering improved aesthetics and reduced pain.
- Further research with larger patient cohorts and extended follow-up is recommended to confirm long-term oncological efficacy.
